Goldman Sachs SELL

AstraZeneca (AZN)

Aug 17, 20267 pages页

From the report报告摘录Oncology Catalysts: Saffron trial positive (expands Tagrisso in 2L EGFR+ MET+ NSCLC, differentiates from competitors), Destiny-Lung04 positive (validates HER2+ NSCLC standard-of-care, $900m peak sales model)…

Read the full report + PDF阅读全文与 PDF

The full summary (3 key points) and the original Goldman Sachs PDF are for MastermindX Pro members. 完整摘要（3 个要点）与 Goldman Sachs 原始 PDF 为 MastermindX Pro 会员专享。

Read on MastermindX前往 MastermindX 阅读

Related institutional research相关机构研报

Not investment advice. MastermindX hosts third-party institutional research for reference and education; ratings and views are the authors', not ours. Browse the full Research Vault → 非投资建议。MastermindX 仅收录第三方机构研究，供参考与学习；其中评级与观点均属作者本人。浏览完整研报库 →